Although low-molecular-mass hyaluronan (LMMHA) has been implicated in pulmonary inflammatory diseases, the signalling pathway of LMMHA (200 000 molecular weight) that initiates the inflammatory response in lung is still unknown. In this study, we evaluate the role of phosphoinositide 3-kinase (PI3K) and its downstream signalling pathway in LMMHA-induced lung inflammatory responses. Our results indicate that pharmacological inhibition of PI3K or genetic deletion of Akt1 enhances neutrophil apoptosis, attenuates neutrophil influx into the lungs of mice and diminishes the expression of pro-inflammatory factors such as interleukin-6, keratinocyte cell-derived chemokine and promatrix metalloproteinase-9 in bronchoalveolar lavage fluid after intratracheal administration of LMMHA. More importantly, we found that PI3K/Akt1 participates in LMMHA-induced inflammatory responses, which are mainly mediated by the myeloid leukaemia cell differentiation protein (Mcl-1). Our study suggests that LMMHA induced significantly increased levels of inflammatory factors in bronchoalveolar lavage fluid and activation of the PI3K/Akt1 pathway, which up-regulates the expression of the anti-apoptotic protein Mcl-1 and inhibits the activation of caspase-3, thereby suppressing neutrophil apoptosis to trigger lung inflammation. These findings reveal a novel molecular mechanism underlying sterile inflammation and provides a new potential target for the treatment of pulmonary disease.
Introduction
Hyaluronan (or hyaluronic acid, HA), a major extracellular matrix (ECM) component, is a non-sulphated glycosaminoglycan composed of repeating polymeric disaccharides D-glucuronic acid and N-acetyl-D-glucosamine linked by a glucuronidic bond. 1 Hyaluronan regulates many aspects of molecular mechanisms of tissue repair, such as activation of inflammatory cells to mount an immunological response. 2 Low-molecular-mass HA (LMMHA), a product of rapid turnover and degradation of HA, can serve as an intracellular signalling molecule in inflammation and has been found to be pro-inflammatory. 3 LMMHA is dramatically increased in patients with idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma and acute respiratory distress Abbreviations: BALF, bronchoalveolar lavage fluid; ECM, extracellular matrix; ERK 1/2, extracellular signal-regulated kinase 1/2; IFN-b, interferon-b; IL-1b, interleukin-1b; IRF-3, interferon regulatory factor 3; KC, keratinocyte cell-derived chemokine; LMMHA, low-molecular-mass hyaluronan; Mcl-1, myeloid leukaemia cell differentiation protein; MMP-9, matrix metalloproteinase-9; MPO, myeloperoxidase; PBS, phosphate-buffered saline; PI3K, phosphoinositide 3-kinase; TLR, Toll-like receptor; WT, wild-type ª 2018 John Wiley & Sons Ltd, Immunology, 155, 387-395 syndrome. [4] [5] [6] [7] A previous study on the role of LMMHA in lung injury revealed that blocking the effect of LMMHA with specific peptides decreases neutrophil infiltration and fibrosis activity and alleviates lung tissue damage in a bleomycin-mediated LMMHA-induced mouse lung injury model. 8 These studies establish the importance of LMMHA in respiratory disorders and encourage further study of the pro-inflammatory properties of LMMHA.
In previous studies on the response to LMMHA stimulation, murine macrophages were identified as the principle effector cells in the production of pro-inflammatory cytokines and chemokines. 9 Furthermore, LMMHA has the potential to induce the production of pro-inflammatory cytokines in airway epithelial cells, as well as the ability to up-regulate adhesion molecules in endothelial cells. 10, 11 Many pro-inflammatory mediators also play a key role in LMMHA-mediated lung inflammatory responses including keratinocyte cell-derived chemokine (KC), interleukin-1b (IL-1b), IL-6, macrophage inflammatory protein 2 and tumour nerosis factor-a. 12, 13 It is known that IL-6 is an important inflammatory factor that has the ability to enhance the adhesion and aggregation of neutrophils and delay spontaneous apoptosis of neutrophils.
14 Matrix metalloproteinase 9 (MMP9) stored in the tertiary granules of neutrophils is a protease with the potential to catalyse the ECM component and produce active forms of pro-inflammatory cytokines and chemokines, thereby contributing to tissue remodelling and inflammatory responses. 15, 16 In large quantities, LMMHA may promote inflammatory responses by endowing structural and immune cells with pro-inflammatory phenotypes. Although there are limited and contradictory reports on neutrophil migration in the context of LMMHA-mediated responses, 17 the critical role of neutrophils in inflammatory pulmonary diseases is well studied. 18 Direct study of the LMMHA effect on the airway system is scarce, and despite the evidence that supports the pro-inflammatory effects of LMMHA, the molecular mechanism by which LMMHA drives or regulates the inflammatory reaction has been incompletely investigated.
In this study, an in vivo system was used to mimic the stressed environment by intratracheal administration of LMMHA. Our studies demonstrate for the first time that phosphoinositide 3-kinase (PI3K)/Akt1 signalling plays a critical role in LMMHA (200 000 MW) -induced lung inflammation. More importantly, the PI3K/Akt1 pathway is shown to be responsible for delaying lung neutrophil apoptosis, and the anti-apoptotic molecule myeloid leukaemia cell differentiation protein (Mcl-1) was identified as a downstream molecule in LMMHA-inhibited neutrophil apoptosis. These new findings will surely offer a new perspective to our understanding of molecular mechanisms involved in pulmonary diseases.
Materials and methods

Mice and LMMHA administration
Wild-type control mice (C57BL/6J) were purchased from the Jackson Laboratory (Bar Harbor, ME). Akt1 À/À mice were provided by Taconic (Rensselaer, NY). The LMMHA (200 000 MW) intratracheal mouse model was generated as described previously. 13 The mice were given 50 ll of wortmannin (40 lg/kg), LY294002 (2 mg/kg), or 0Á1% dimethyl sulphoxide (DMSO) vehicle by intranasal administration before LMMHA treatment. All procedures involving mice were approved and monitored by Zhejiang University of Technology.
Bronchoalveolar lavage fluid
The trachea was exposed through a midline incision and cannulated with a sterile 22-gauge needle. Bronchoalveolar lavage fluid (BALF) was obtained by instilling and collecting four 0Á5-ml volumes of cold phosphate-buffered saline (PBS) through the incised trachea. BALF was performed three times and 1Á4 ml of lavage fluid was retrieved per mouse. Each BALF sample was centrifuged, and the supernatants were stored at À80°until use. Total cell numbers in BALF were counted from each sample in a haemocytometer. BALF neutrophil counts were determined on/in cytospin preparations stained with a Diff-Quickstaining kit (IMEB, San Marcos, CA).
12,13
Enzyme-linked immunosorbent assay Interleukin-6, KC and pro-MMP9 were measured in the BALF using mouse enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol.
Neutrophil detection and activity identification in lung tissues
To detect the infiltration of neutrophils in the lung, tissue sections were fixed in formalin for 24 hr, followed by paraffin-embedding. Neutrophils were measured with a histochemical Leder stain for naphthol-ASD-chloroacetate esterase. For the analysis of lung neutrophil activity, flushed lungs were excised, digested in RPMI-1640 medium containing 5% fetal bovine serum, 20 U/ml collagens, and 1 lg/ml DNase I, and incubated at 37°for 60 min. The remaining lung tissue was disrupted by passage through a 21-gauge needle. Cell pellets were resuspended for further analysis. Lung neutrophils were positively selected using an anti-Ly-6G monoclonal antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) as described previously.
Myeloperoxidase assay
For myeloperoxidase (MPO) activity analysis, lung tissues were perfused to remove all blood, frozen in liquid nitrogen and stored at À80°for use. The homogenates were prepared in lysis buffer that consisted of 200 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl, 10% glycerine, 1 mM PMSF, 1 lg/ml leupeptin and 28 lg/ml aprotinin (pH 7Á4). This mixture was centrifuged at 4°at 1500 g for 15 min. Supernatants were diluted at a ratio of 1 : 4 and subjected to MPO analysis following the manufacturer's protocol (Hycult Biotechnology, Uden, the Netherlands). MPO activity was determined by absorbance at 450 nm.
Examination of protein expression and kinase phosphorylation
Neutrophil extracts were prepared using the neutrophil isolation kit (Miltenyi Biotec). The protein concentration was assayed using the BCA protein assay (Pierce, Rockford, IL). For the immunoblot analysis, 500 lg of total protein was separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore). After being blocked, the membrane was incubated overnight at 4°with antibody to phos-and total-Akt1, p38, extracellular signalregulated kinase 1/2 (ERK1/2), b-actin or Mcl-1 using a dilution of 1 : 1000, followed by horseradish peroxidasecoupled secondary antibody at a dilution of 1 : 2000. All antibodies were purchased from Cell Signaling Technology (Danvers, MA). The signals were detected using chemiluminescence Western blot detection reagents (ECL Detection System, Amersham Pharmacia Biotech, Piscat-away, NJ).
Real-time PCR
RNA was extracted from neutrophils using TRIzol (Invitrogen, Carlsbad, CA). cDNA was synthesized using the superscript TM first-strand synthesis system (Invitrogen). Real-time PCR analysis was performed on the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA) using the Quantitect SYBR Green PCR kit, as recommended by the manufacturer (Qiagen, Hilden, Germany). Specific primers were as follows:
. The relative value of target gene expression was calculated from the standardized target gene and b-actin amplified curves.
Assessment of neutrophil apoptosis and caspase-3 activity
Cells from BALF (1 9 10 6 cells/ml) were incubated with Annexin V-FITC and propidium iodide (BD Biosciences, San Jose, CA) for 15 min in the dark at room temperature. Cells were analysed with FACS Calibur (Becton Dickinson, Franklin Lakes, NJ). Neutrophils were identified by forward-scatter versus side-scatter characteristics and by Ly6G staining. 19, 20 Data analysis was performed with CELL QUEST software (Becton Dickinson, Franklin Lakes, NJ). To analyse caspase-3 activity in neutrophils, a caspase-3 colorimetric activity assay kit (BioVision Research Products, Milpitas, CA) was applied in accordance with the manufacturer's instructions. Cell lysates, prepared from 5 9 10 6 neutrophils, were incubated with a labelled DEVD-pNA substrate at 37°for 1Á5 hr. The pNA light emission was quantified using a microtitre plate reader at 405 nm.
Statistical analysis
All data were expressed as mean AE SEM. The Tukey-Kramer multiple comparisons test and a one-way analysis of variance were used for multiple groups, followed by Student's t-test for comparisons between two groups. Values of P < 0Á05 were considered significant.
Results
LMMHA induces lung inflammation following intratracheal administration
Hyaluronan fragments, representing the molecules frequently found at inflammatory sites in the lung, 21 with a molecular mass of 200 000 are known to induce lung inflammation; 12, 13 however, the effect of LMMHA (200 000 MW) on neutrophil activity during the very early stages of lung inflammation in vivo is still unknown. A single intratracheal dose of LMMHA (200 000 MW, 65 mg/kg) resulted in a remarkable increase in total cell and neutrophil counts in BALF (Fig. 1a) . To further quantify the sequestration of neutrophils, MPO activity in the lung tissue was measured. The results demonstrate a substantial increase in MPO activity in LMMHA-treated mice 6 hr after LMMHA administration (Fig. 1b) . Esterase staining of lung tissue consistently indicates that the neutrophils infiltrate the lung in response to LMMHA administration (Fig. 1c) . To further characterize the inflammatory response triggered by LMMHA in the airway, levels of pro-inflammatory cytokines and chemokines in BALF were examined. Production of IL-6 and KC was rapidly induced when the mice were given LMMHA (Fig. 1d) . Importantly, we found that pro-MMP9, a protease involved in the degradation of ECM and the processing of cytokines and chemokines, was also released into the BALF at this early stage (Fig. 1e) . Hence, intratracheal administration of LMMHA causes lung inflammation and results in neutrophils infiltration into the lungs of the mice.
Akt1 signalling is critical in LMMHA-induced neutrophilic inflammation
Because the suppression of neutrophil apoptosis in acute lung injury is associated with the Akt-signalling pathway, 22 we investigated the molecular mechanism by which LMMHA (200 000 MW) drives the neutrophilic response in the airway system. Western blot analysis of lung homogenates revealed a more potent and sustained activation of Akt1 in the LMMHA-challenged lungs than in that of mice treated with PBS (Fig. 2a) . The phosphorylation of Akt1 in lung neutrophils was also remarkably induced at 6 hr following LMMHA administration (Fig. 2b) . Moreover, the phosphorylation of p38 and ERK1/2 was significantly decreased in Akt1 À/À mouse neutrophils compared with those of wild-type (WT) mice after intratracheal administration of LMMHA (Fig. 2c ).
This indicates that Akt1 plays a pivotal role in regulating LMMHA-induced neutrophil activity.
To further demonstrate the role of Akt1 in LMMHAmediated airway inflammatory responses, WT and Akt1 À/À mice were exposed to LMMHA. Neutrophil recruitment into the lung was remarkably decreased by a deficiency in Akt1, demonstrated by BALF neutrophil counts (Fig. 3a) . Since decreased neutrophil accumulation is the result of either impaired sequestration of neutrophils into lungs or the defective migration of neutrophils in the tissue, an MPO assay was conducted. Our results show a significant reduction in MPO activity in Akt1 À/À mice (Fig. 3b) , which suggests the need for Akt1 signalling in neutrophil extravasation. Furthermore, the substantial elevations of IL-6, KC and pro-MMP9 in BALF induced by LMMHA stimulation have been compromised in Akt1 À/À mice (Fig. 3c ). This suggests that Akt1 signalling selectively influences the generation of inflammatory mediators.
PI3K participates in LMMHA-induced inflammatory response
Given that Akt1 is involved in LMMHA-induced lung inflammation, we sought to extend the understanding of this pathway by identifying the upstream and downstream molecule(s) in this cascade. It is known that PI3K is the most primary upstream molecule of a large number of pathways including the Akt1 pathway, 23 so the involvement of PI3K in LMMHA-induced lung inflammation was examined. Through the application of the PI3K-specific inhibitor wortmannin before LMMHA administration, we found that LMMHA-triggered Akt1 phosphorylation in neutrophils was significantly reduced upon PI3K inhibition (Fig. 4a) , which indicates the dependency of Akt1 activation on PI3K. Further demonstrating the functional relevance of PI3K, a greater reduction in BALF neutrophils was observed in mice pretreated with wortmannin than in those treated only with PBS (Fig. 4b) . Furthermore, blockade of PI3K with wortmannin induced a marked reduction in MPO activity (Fig. 4c) , which is associated with a decrease in the levels of IL-6, KC and pro-MMP9 in BALF (Fig. 4d,e) . Therefore, PI3K plays an essential role in LMMHA-induced airway responses, and Akt1 is a downstream target activated by PI3K in the inflammatory signalling pathway.
PI3K/Akt1 regulates LMMHA-induced neutrophil apoptosis through Mcl-1
Because of a profound decrease in BALF neutrophil numbers induced by either pharmacological inhibition of PI3K or genetic deletion of Akt1, PI3K/Akt1 signalling was found to be responsible for the LMMHA-induced neutrophil counts in the lungs (Figs 3a and 4b) . After considering the well-recognized role of Akt1 in mediating survival signals in diverse cells, [24] [25] [26] it was hypothesized that Akt1 may have a regulatory role in sustaining neutrophil lifespan. To address this possibility, apoptosis of BALF neutrophils from WT and Akt1 À/À mice was evaluated by flow cytometry. The analysis revealed that the number of apoptotic neutrophils in BALF was significantly higher in Akt1 À/À mice than in WT mice at 18 hr after LMMHA administration (Fig. 5a ). Next, we determined the role of PI3K in neutrophil apoptosis and observed a similar increase in neutrophil apoptosis in mice treated with wortmannin or LY2940002 (Fig. 5a ). Apoptosis of neutrophils was further corroborated by increased caspase-3 activities when PI3K/Akt1 signalling was blocked (Fig. 5b) . Hence, PI3K/Akt1 signalling promotes neutrophil survival. To investigate the mechanisms behind the neutrophilprotecting effects of LMMHA, potential downstream components were examined. As Bcl-2 family members constitute a network of anti-apoptotic regulators, and some of these regulators have been proved to be closely associated with Akt signalling, 27 our initial targets were these Bcl-2 family members. Bcl-2 and Bcl-X existed at almost undetectable levels in the accumulated lung neutrophils (data not shown), as is consistent with the previous findings. 28 When anti-apoptotic protein Mcl-1 was analysed in BALF neutrophils after LMMHA stimulation, its mRNA and protein levels were significantly increased. Nevertheless, Mcl-1 levels were markedly decreased in Akt1 À/À neutrophils and in neutrophils from mice treated with wortmannin or LY2940002 (Fig. 5c,d ). These results indicate that PI3K/Akt1 signalling plays a regulatory role of in Mcl-1 production. More importantly, the decreased expression of Mcl-1 upon Akt1 deletion or PI3K inhibition was inversely related to neutrophil apoptosis and to caspase-3 activities (Fig. 5b,c,d ). Therefore, we conclude that Mcl-1 functions as the downstream target of the PI3K/Akt1 pathway in inhibiting neutrophil apoptosis in this setting (Fig. 6) .
Discussion
In the present study, our data demonstrate that intratracheal administration of LMMHA triggers lung inflammation and induces a dramatic infiltration of neutrophils into the interstitial and intra-alveolar compartments in mice. This is consistent with previous studies that show IL-6 and KC are significantly elevated in LMMHAinduced lung injury. 12,13 Notably, we found that the level of pro-MMP9, a pro-inflammatory cytokine MMP9 precursor, was remarkably increased in BALF. MMP9 has been shown to be related to several inflammatory lung diseases, such as chronic obstructive pulmonary disease, asthma and acute respiratory distress syndrome. [29] [30] [31] Hence, the participation of pro-MMP9 highlights the importance of this protease in LMMHA-induced inflammation response. The catalytic property of MMP9 enables it to degrade extracellular structures and facilitate the extravasation and migration of neutrophils, so promoting neutrophilic inflammation.
Despite evidence that supports the critical role of LMMHA in airway inflammatory disorders, its signalling pathway in vivo is not clearly understood. Akt1, a member of the three serine/threonine protein kinase families (Akt1, Akt2, Akt3), is expressed profusely and ubiquitously in the cytoplasm. The other two isoforms are localized to certain tissues and subcellular loci. Several studies have suggested that Akt1 plays an extensive role in regulating cell survival, differentiation and proliferation. 32, 33 Akt1 was recently identified as a crucial regulator in inflammatory responses. 34 Although previous studies have shown that Akt1 activation in murine macrophages enhances lipopolysaccharide-induced inflammatory responses, 35 the importance of Akt1 in LMMHA-challenged inflammatory neutrophils had not been elucidated. Here, we report that phosphorylation of Akt1 in pulmonary neutrophils was significantly elevated following administration of LMMHA. Both p38 and ERK1/2 phosphorylation in lung neutrophils were significantly reduced in Akt1 WT mice. Additionally, we found that the severity of inflammatory responses in Akt1 À/À mice was remarkably weaker than that in WT mice. These data demonstrate that Akt1-mediated signalling contributes to LMMHAinduced neutrophil activity. We propose that Akt1 influences neutrophil activity consistently. This is in accordance with the sustained activation of Akt1 during the response. Activation of PI3K leads to generation of the 3 0 hydroxyl group of phosphatidylinositols, which function as secondary messengers in the recruitment and activation of a number of kinase enzymes, including phosphoinositidedependent kinase-1, protein kinase B/Akt, and several protein kinase C isoforms.
36 PI3K/Akt signalling pathways negatively regulate lipopolysaccharide-induced acute inflammatory responses in vitro. 37 Moreover, inhibition of PI3K/Akt signalling pathways have been shown to block tumour necrosis factor-stimulated gene 6-mediated acute airway inflammation and hyper-responsiveness in response to ozone or short-fragment HA. 38 Here we confirm that the inclusion of PI3K as an upstream activator of Akt1 was confirmed by using specific inhibitors, wortmannin and LY2940002, which consistently suppressed Akt1 phosphorylation and neutrophil counts. Akt1 is regulated by PI3K in LMMHA-induced neutrophil responses. These results suggest that the PI3K/Akt1 pathway is activated in LMMHA-induced lung inflammation and wortmannin or LY2940002 pre-treatment markedly reduced the LMMHA-induced phosphorylation of Akt1. This is consistent with the previous studies that show that inhibition of the PI3K/Akt signalling pathway exerts a protective role in lung inflammatory responses. 39 Given the importance of the PI3K/Akt1 pathway in transmitting anti-apoptotic signalling in neutrophils, we hypothesize that in addition to their direct inflammation-promoting properties, these molecules may have an effect on the neutrophil lifespan. Indeed, when apoptosis of BALF neutrophils from LMMHA-treated mice was examined in detail, an increase in apoptotic neutrophils was observed in Akt1 À/À mice compared with WT mice. This phenomenon was reproduced in the mice with PI3K inhibition, which supports the notion that LMMHA-activated PI3K/Akt1 signalling is capable of sustaining the lifespan of neutrophils. Recently, studies have reported that Mcl-1 plays an inhibitory role in apoptosis. 40 In our experiments, we show that LMMHA-induced up-regulation of Mcl-1 was markedly decreased by the abrogation of PI3K/Akt1, at either the mRNA or the protein level. This suggests that PI3K/Akt1 participates in the transcription of Mcl-1. Our identification of Mcl-1 as a major component of the LMMHA-induced neutrophil survival pathway, operating mostly downstream of PI3K/Akt1, uncovers a previously unknown signalling molecule in LMMHA-mediated neutrophil apoptosis. Caspase-3 is known to be a key performer downstream of cell apoptosis. We observed that caspase-3 activity is significantly elevated in the absence of Akt1, or PI3K inhibition is inversely related to Mcl-1 levels. It was shown that LMMHA-induced neutrophil apoptosis is regulated by downstream signalling molecules Mcl-1 and caspase-3 of the PI3K/Akt1 signalling pathway. This suggests that the high expression of Mcl-1 and inhibition of caspase-3 activity are important mechanisms of LMMHA-induced delayed apoptosis of pulmonary neutrophils. Based on the above findings, we propose that LMMHA-induced PI3K/Akt1 signalling, in cooperation with Mcl-1, not only induces neutrophil activation and recruitment, but also prevents neutrophils from constitutive apoptosis, thereby amplifying and prolonging the acute inflammatory response.
PI3K/Akt1-regulated pro-inflammatory responses additionally correlate with the Toll-like receptor (TLR) signalling pathway. 41 Several studies have shown that Akt1 expression has a significant inhibitory effect on the TLR4 pathway and impairs interferon-b (IFN-b) promoter activity by suppressing IFN regulatory factor 3 (IRF3) activity in the Toll/IL-1 receptor domain-containing adapter-inducing IFN-b-dependent pathway in vitro. 42 Our previous studies revealed severe inflammatory infiltration in the alveolar space of IRF3
À/À and IFN-b À/À mice within 24 hr after LMMHA (200 000 MW) intratracheal administration. Levels of IFN-b were also decreased in TLR4-deficient neutrophils compared with those of WT neutrophils, leading to impaired apoptosis of neutrophils and abnormal accumulation of neutrophils in the lungs of LMMHA-treated mice. 12,13 Consequently, we hypothesized that Akt1 inhibits neutrophil apoptosis in LMMHAinduced pulmonary inflammation associated with the TLR4 pathway, which acts as a negative regulator of TLR4, and distinctively suppresses IRF3 activity and decrease the levels of IFN-b in triggering inflammation. Although the exact relationship and mechanisms of action require further experiments to verify, these findings help to extend our understanding of the biological function of LMMHA in the airway system.
In conclusion, our results demonstrate that LMMHA (200 000 MW) is a critical signal in neutrophil activation and attraction, leading to lung inflammation. Moreover, LMMHA-challenged PI3K/Akt1 signalling through the up-regulation of the expression of the anti-apoptotic protein Mcl-1 delays lung neutrophil apoptosis. Therefore, a novel PI3K/Akt1-dependent pathway may contribute to the LMMHA-triggered inflammatory response in the airway system. Hence, inhibition of the PI3K/Akt1 pathway exerts a protective role in LMMHA-induced lung inflammation. Our study sheds a light on the functions and mechanisms of specific ECM fragments in the airway response and helps to improve our understanding of the pathogenesis of pulmonary inflammatory diseases, so providing new information on novel target molecules for treatment.
